FDA sets out clinical trial safety rules

The FDA has announced its new rules for clinical trials. Clinical trial moderators now have 15 days to inform the FDA of higher adverse reactions and risks to participants. "This final rule will expedite FDA's review of critical safety information and help the agency monitor the safety of investigational drugs and biologics," says Rachel Behrman, Associate Director for Medical Policy in the FDA's Center for Drug Evaluation and Research, in a statement. FDA release | Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.